Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
I, too, wanted to express how devastated I am over losing our colleague Helen Branswell. She was kind, scrupulous, brilliant, and truly inspiring in action. Thank you, Helen.
The need-to-know this morning
- Privately held U.K. biotech OMass Therapeutics raised $310 million to support the clinical development of a drug to treat congenital adrenal hyperplasia, an inherited endocrine disorder.
- The investment firm Orbimed raised nearly $3 billion for two, new private equity funds that will invest in U.S, European and Asian health care companies.
Investor: China’s biotech boom threatens U.S. venture capital
From STAT’s Allison DeAngelis: The rise of Chinese biotech isn’t just impacting U.S. companies, one investor is warning. It’s threatening VC firms.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.